{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:51:20Z","timestamp":1772164280186,"version":"3.50.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"22","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The pathophysiology of tumor growth following skeletal metastases and the poor response of this type of lesion to therapeutic intervention remains incompletely understood. Vascular endothelial growth factor (VEGF)-A and its receptors play a role in both osteoclastogenesis and tumor growth. Systemic (i.v.) treatment of nude mice bearing intrafemoral prostate (PC-3) tumors with the vascular ablative agent VEGF121\/recombinant gelonin (rGel) strongly inhibited tumor growth. Fifty percent of treated animals had complete regression of bone tumors with no development of lytic bone lesions. Immunohistochemical analysis showed that VEGF121\/rGel treatment suppressed tumor-mediated osteoclastogenesis in vivo. In vitro treatment of murine osteoclast precursors, both cell line (RAW264.7) and bone marrow\u2013derived monocytes (BMM), revealed that VEGF121\/rGel was selectively cytotoxic to osteoclast precursor cells rather than mature osteoclasts. VEGF121\/rGel cytotoxicity was mediated by Flt-1, which was down-regulated during osteoclast differentiation. Analysis by flow cytometry and reverse transcription-PCR showed that both BMM and RAW264.7 cells display high levels of Flt-1 but low levels of Flk-1. Internalization of VEGF121\/rGel into osteoclast precursor cells was suppressed by pretreatment with an Flt-1 neutralizing antibody or by placenta growth factor but not with an Flk-1 neutralizing antibody. Thus, VEGF121\/rGel inhibits osteoclast maturation in vivo and it seems that this process is important in the resulting suppression of skeletal osteolytic lesions. This is a novel and unique mechanism of action for this class of agents and suggests a potentially new approach for treatment or prevention of tumor growth in bone. (Cancer Res 2006; 66(22): 10919-28)<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-0459","type":"journal-article","created":{"date-parts":[[2006,11,15]],"date-time":"2006-11-15T21:46:18Z","timestamp":1163627178000},"page":"10919-10928","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Inhibition of Prostate Tumor Growth and Bone Remodeling by the Vascular Targeting Agent VEGF121\/rGel"],"prefix":"10.1158","volume":"66","author":[{"given":"Khalid A.","family":"Mohamedali","sequence":"first","affiliation":[{"name":"1Experimental Therapeutics and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann T.","family":"Poblenz","sequence":"additional","affiliation":[{"name":"1Experimental Therapeutics and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles R.","family":"Sikes","sequence":"additional","affiliation":[{"name":"2Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora M.","family":"Navone","sequence":"additional","affiliation":[{"name":"2Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip E.","family":"Thorpe","sequence":"additional","affiliation":[{"name":"3Department of Pharmacology, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryant G.","family":"Darnay","sequence":"additional","affiliation":[{"name":"1Experimental Therapeutics and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Rosenblum","sequence":"additional","affiliation":[{"name":"1Experimental Therapeutics and Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2006,11,15]]},"reference":[{"key":"2022061622151201000_B1","doi-asserted-by":"crossref","unstructured":"Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate\u20081999; 39: 246\u201361.","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U"},{"key":"2022061622151201000_B2","doi-asserted-by":"crossref","unstructured":"Lange PH, Vessella RL. Mechanisms, hypotheses, and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev\u20081998; 17: 331\u20136.","DOI":"10.1023\/A:1006106209527"},{"key":"2022061622151201000_B3","unstructured":"Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol\u20081987; 13: 41\u20139."},{"key":"2022061622151201000_B4","doi-asserted-by":"crossref","unstructured":"Guise TA, Chirgwin JM. Transforming growth factor-\u03b2 in osteolytic breast cancer bone metastases. Clin Orthop Relat Res\u20082003; 415S: S32\u20138.","DOI":"10.1097\/01.blo.0000093055.96273.69"},{"key":"2022061622151201000_B5","doi-asserted-by":"crossref","unstructured":"Kumta SM, Huang L, Cheng YY, et al. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci\u20082003; 73: 1427\u201336.","DOI":"10.1016\/S0024-3205(03)00434-X"},{"key":"2022061622151201000_B6","unstructured":"Nakata A, Tsujimura T, Sugihara A, et al. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res\u20081999; 19: 4131\u20138."},{"key":"2022061622151201000_B7","unstructured":"Bendre MS, Gaddy-Kurten D, Mon-Foote T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res\u20082002; 62: 5571\u20139."},{"key":"2022061622151201000_B8","unstructured":"Arora N, Masood R, Zheng T, et al. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res\u20081999; 59: 183\u20138."},{"key":"2022061622151201000_B9","doi-asserted-by":"crossref","unstructured":"Duvic M, Cather J, Maize J, Frankel AE. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol\u20081998; 58: 87\u201390.","DOI":"10.1002\/(SICI)1096-8652(199805)58:1<87::AID-AJH18>3.0.CO;2-2"},{"key":"2022061622151201000_B10","unstructured":"Osborne CK, Coronado-Heinsohn E. Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF). Cancer J Sci Am\u20081996; 2: 175."},{"key":"2022061622151201000_B11","unstructured":"Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR\/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res\u20081996; 56: 1324\u201330."},{"key":"2022061622151201000_B12","doi-asserted-by":"crossref","unstructured":"O'Farrell AM, Yuen HA, Smolich B, et al. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res\u20082004; 28: 679\u201389.","DOI":"10.1016\/j.leukres.2003.11.004"},{"key":"2022061622151201000_B13","doi-asserted-by":"crossref","unstructured":"Paz K, Zhu Z. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front Biosci\u20082005; 10: 1415\u201339.","DOI":"10.2741\/1629"},{"key":"2022061622151201000_B14","unstructured":"Brekken RA, Overholser JP, Stastny VA, et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR\/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res\u20082000; 60: 5117\u201324."},{"key":"2022061622151201000_B15","doi-asserted-by":"crossref","unstructured":"Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun\u20082005; 333: 328\u201335.","DOI":"10.1016\/j.bbrc.2005.05.132"},{"key":"2022061622151201000_B16","doi-asserted-by":"crossref","unstructured":"Ruan GR, Liu YR, Chen SS, et al. Effect of antisense VEGF cDNA transfection on the growth of chronic myeloid leukemia K562 cells in vitro and in nude mice. Leuk Res\u20082004; 28: 763\u20139.","DOI":"10.1016\/j.leukres.2003.11.017"},{"key":"2022061622151201000_B17","unstructured":"Ueda Y, Yamagishi T, Ikeya H, et al. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo. Anticancer Res\u20082004; 24: 3009\u201317."},{"key":"2022061622151201000_B18","doi-asserted-by":"crossref","unstructured":"Veenendaal LM, Jin H, Ran S, et al. In vitro and in vivo studies of a VEGF121\/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A\u20082002; 99: 7866\u201371.","DOI":"10.1073\/pnas.122157899"},{"key":"2022061622151201000_B19","doi-asserted-by":"crossref","unstructured":"Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem\u20082001; 276: 3222\u201330.","DOI":"10.1074\/jbc.M002016200"},{"key":"2022061622151201000_B20","doi-asserted-by":"crossref","unstructured":"McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist\u20082000; 5 Suppl 1: 3\u201310.","DOI":"10.1634\/theoncologist.5-suppl_1-3"},{"key":"2022061622151201000_B21","doi-asserted-by":"crossref","unstructured":"Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res\u20081995; 67: 281\u2013316.","DOI":"10.1016\/S0065-230X(08)60716-2"},{"key":"2022061622151201000_B22","doi-asserted-by":"crossref","unstructured":"Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG. The vascular-ablative agent VEGF (121)\/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia\u20082005; 7: 486\u201396.","DOI":"10.1593\/neo.04631"},{"key":"2022061622151201000_B23","doi-asserted-by":"crossref","unstructured":"Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification, and angiogenesis during endochondral bone formation. Nat Med\u20081999; 5: 623\u20138.","DOI":"10.1038\/9467"},{"key":"2022061622151201000_B24","doi-asserted-by":"crossref","unstructured":"Matsumoto Y, Tanaka K, Hirata G, et al. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol\u20082002; 168: 5824\u201331.","DOI":"10.4049\/jimmunol.168.11.5824"},{"key":"2022061622151201000_B25","doi-asserted-by":"crossref","unstructured":"Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med\u20081999; 190: 293\u20138.","DOI":"10.1084\/jem.190.2.293"},{"key":"2022061622151201000_B26","doi-asserted-by":"crossref","unstructured":"Chen J, De S, Brainard J, Byzova TV. Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun Adhes\u20082004; 11: 1\u201311.","DOI":"10.1080\/15419060490471739"},{"key":"2022061622151201000_B27","unstructured":"Ismail AH, Altaweel W, Chevalier S, Kassouf W, Aprikian AG. Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer. Can J Urol\u20082004; 11: 2146\u201350."},{"key":"2022061622151201000_B28","doi-asserted-by":"crossref","unstructured":"Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res\u20082004; 10: 5137\u201344.","DOI":"10.1158\/1078-0432.CCR-03-0434"},{"key":"2022061622151201000_B29","doi-asserted-by":"crossref","unstructured":"Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res\u20082004; 64: 994\u20139.","DOI":"10.1158\/0008-5472.CAN-03-1382"},{"key":"2022061622151201000_B30","doi-asserted-by":"crossref","unstructured":"Shariat SF, Anwuri VA, Lamb DJ, et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol\u20082004; 22: 1655\u201363.","DOI":"10.1200\/JCO.2004.09.142"},{"key":"2022061622151201000_B31","doi-asserted-by":"crossref","unstructured":"Kitagawa Y, Dai J, Zhang J, et al. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res\u20082005; 65: 10921\u20139.","DOI":"10.1158\/0008-5472.CAN-05-1809"},{"key":"2022061622151201000_B32","unstructured":"Yang J, Fizazi K, Peleg S, et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res\u20082001; 61: 5652\u20139."},{"key":"2022061622151201000_B33","doi-asserted-by":"crossref","unstructured":"Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene\u20081999; 18: 2221\u201330.","DOI":"10.1038\/sj.onc.1202527"},{"key":"2022061622151201000_B34","doi-asserted-by":"crossref","unstructured":"Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature\u20082003; 423: 337\u201342.","DOI":"10.1038\/nature01658"},{"key":"2022061622151201000_B35","doi-asserted-by":"crossref","unstructured":"Kim S, Koga T, Isobe M, et al. Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Genes Dev\u20082003; 17: 1979\u201391.","DOI":"10.1101\/gad.1119303"},{"key":"2022061622151201000_B36","doi-asserted-by":"crossref","unstructured":"Odgren PR, Kim N, MacKay CA, et al. The role of RANKL (TRANCE\/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue. Connect Tissue Res\u20082003; 44 Suppl 1: 264\u201371.","DOI":"10.1080\/03008200390181753"},{"key":"2022061622151201000_B37","doi-asserted-by":"crossref","unstructured":"Karsenty G. The genetic transformation of bone biology. Genes Dev\u20081999; 13: 3037\u201351.","DOI":"10.1101\/gad.13.23.3037"},{"key":"2022061622151201000_B38","doi-asserted-by":"crossref","unstructured":"Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol\u20082001; 19: 3562\u201371.","DOI":"10.1200\/JCO.2001.19.15.3562"},{"key":"2022061622151201000_B39","doi-asserted-by":"crossref","unstructured":"Engsig MT, Chen QJ, Vu TH, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol\u20082000; 151: 879\u201389.","DOI":"10.1083\/jcb.151.4.879"},{"key":"2022061622151201000_B40","doi-asserted-by":"crossref","unstructured":"Henriksen K, Karsdal M, Delaisse JM, Engsig MT. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1\/2-dependent mechanism. J Biol Chem\u20082003; 278: 48745\u201353.","DOI":"10.1074\/jbc.M309193200"},{"key":"2022061622151201000_B41","doi-asserted-by":"crossref","unstructured":"Haigh JJ, Gerber HP, Ferrara N, Wagner EF. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development\u20082000; 127: 1445\u201353.","DOI":"10.1242\/dev.127.7.1445"},{"key":"2022061622151201000_B42","doi-asserted-by":"crossref","unstructured":"Zelzer E, McLean W, Ng YS, et al. Skeletal defects in VEGF (120\/120) mice reveal multiple roles for VEGF in skeletogenesis. Development\u20082002; 129: 1893\u2013904.","DOI":"10.1242\/dev.129.8.1893"},{"key":"2022061622151201000_B43","doi-asserted-by":"crossref","unstructured":"Carlevaro MF, Cermelli S, Cancedda R, Descalzi CF. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. J Cell Sci\u20082000; 113: 59\u201369.","DOI":"10.1242\/jcs.113.1.59"},{"key":"2022061622151201000_B44","doi-asserted-by":"crossref","unstructured":"Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood\u20082001; 97: 785\u201391.","DOI":"10.1182\/blood.V97.3.785"},{"key":"2022061622151201000_B45","doi-asserted-by":"crossref","unstructured":"Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood\u20081996; 87: 3336\u201343.","DOI":"10.1182\/blood.V87.8.3336.bloodjournal8783336"},{"key":"2022061622151201000_B46","doi-asserted-by":"crossref","unstructured":"Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A\u20081998; 95: 9349\u201354.","DOI":"10.1073\/pnas.95.16.9349"},{"key":"2022061622151201000_B47","doi-asserted-by":"crossref","unstructured":"Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE\u20082001; 2001: RE21.","DOI":"10.1126\/scisignal.1122001re21"},{"key":"2022061622151201000_B48","doi-asserted-by":"crossref","unstructured":"Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med\u20082002; 8: 841\u20139.","DOI":"10.1038\/nm740"},{"key":"2022061622151201000_B49","doi-asserted-by":"crossref","unstructured":"Niida S, Kondo T, Hiratsuka S, et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A\u20082005; 102: 14016\u201321.","DOI":"10.1073\/pnas.0503544102"},{"key":"2022061622151201000_B50","doi-asserted-by":"crossref","unstructured":"Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature\u20082005; 438: 820\u20137.","DOI":"10.1038\/nature04186"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/22\/10919\/2556088\/10919.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/22\/10919\/2556088\/10919.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T21:02:28Z","timestamp":1655413348000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/22\/10919\/526431\/Inhibition-of-Prostate-Tumor-Growth-and-Bone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,15]]},"references-count":50,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2006,11,15]]},"published-print":{"date-parts":[[2006,11,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-0459","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22366064.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366061","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366058.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366061.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366058","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22366064","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6494972.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6494972","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,15]]}}}